Cell TypeGABAergic Projection Neurons
[^1]
LocationStriatum (caudate nucleus, putamen)
[^2]
NeurotransmitterGABA
[^3]
PathologyEarly degeneration in HD
Striatal medium spiny neurons (MSNs) are the principal neurons of the striatum, comprising approximately 90-95% of all striatal neurons. These GABAergic projection neurons are the primary effectors of the basal ganglia motor loop, integrating excitatory cortical and thalamic inputs to modulate movement. In Huntington's disease (HD), MSNs are among the first neuronal populations to degenerate, leading to the characteristic choreiform movements, cognitive deficits, and psychiatric symptoms 1.
| Taxonomy |
ID |
Name / Label |
| Cell Ontology (CL) |
CL:1001474 |
medium spiny neuron |
- Morphology: medium spiny neuron (source: Cell Ontology)
- Morphology can be inferred from Cell Ontology classification
| Database |
ID |
Name |
Confidence |
| Cell Ontology |
CL:1001474 |
medium spiny neuron |
Exact |
¶ Anatomy and Morphology
MSNs possess distinctive morphological features 2:
- Cell body: 10-20 μm diameter, medium-sized
- Dendrites: Highly branched, dense spine coverage (approximately 10,000 spines per neuron)
- Axon: Long, myelinated projection to globus pallidus and substantia nigra
- Spines: Dendritic spines receive ~95% of excitatory synaptic input
MSNs are divided into two populations based on projection target and neurochemical phenotype 3:
| Feature |
D1-MSNs (Direct Pathway) |
D2-MSNs (Indirect Pathway) |
| Dopamine Receptor |
D1R |
D2R |
| Projection |
Substantia nigra pars reticulata (SNr) |
Globus pallidus externus (GPe) |
| Effect on Movement |
Movement initiation |
Movement suppression |
| Pathway |
Direct |
Indirect |
| Neuropeptide |
Dynorphin |
Enkephalin |
- D1 receptors (DRD1): Gs-coupled, increase cAMP, promote movement
- D2 receptors (DRD2): Gi-coupled, decrease cAMP, inhibit movement
- cAMP/PKA pathway: Regulates neuronal excitability
- DARPP-32: Amplifies dopamine signaling
- mTOR pathway: Protein synthesis, synaptic plasticity
- ERK/MAPK pathway: Gene expression, survival
- DRD1: Direct pathway marker
- DRD2: Indirect pathway marker
- PENK: Preproenkephalin (D2-MSNs)
- PDYN: Prodynorphin (D1-MSNs)
- RGS9: Regulator of G-protein signaling
MSNs integrate information to modulate movement 1:
- Direct pathway (D1-MSNs): Facilitate movement by inhibiting SNr output
- Indirect pathway (D2-MSNs): Suppress competing movements via GPe
- Reinforcement learning through reward prediction errors
- Procedural memory formation
- Habit encoding in sensorimotor striatum
- Integrate dopaminergic reward signals
- Modulate goal-directed and habitual behaviors
MSNs are selectively vulnerable in HD due to 2:
- Direct pathway degeneration: D1-MSNs degenerate first
- Indirect pathway involvement: D2-MSNs affected later
- Differential vulnerability: Striosomal MSNs more affected than matrix
The CAG repeat expansion in the HTT gene produces mutant huntingtin protein:
- Polyglutamine expansion: >35 CAG repeats causes disease
- Toxic gain-of-function: mHTT forms aggregates
- Loss of normal function: Disrupted transcription, transport
mHTT disrupts gene expression 3:
- CREB dysfunction: Impaired transcription
- REST dysregulation: Altered neuronal gene expression
- PGC-1α suppression: Mitochondrial dysfunction
- Reduced neurotrophic factors: BDNF, GDNF
Excessive glutamate signaling:
- NMDA receptor overactivation: Calcium influx
- Metabotropic glutamate receptors: mGluR1/5 signaling
- AMPA receptor dysfunction: Altered synaptic transmission
- PGC-1α deficiency: Impaired biogenesis
- Complex I deficiency: Reduced ATP production
- Calcium buffering: Impaired mitochondrial calcium handling
- Oxidative stress: ROS accumulation
- mHTT aggregates: Intraneuronal inclusion bodies
- Autophagy impairment: Defective protein clearance
- Ubiquitin-proteasome dysfunction: Reduced degradation
- Striatal atrophy: 50-70% neuron loss in advanced HD
- Nuclear inclusions: mHTT in neuronal nuclei
- Dendritic spine loss: Reduced synaptic connectivity
- Gliosis: Reactive astrocytosis
- HTT-lowering therapies: ASOs, RNAi, CRISPR
- Small molecule inhibitors: Targeting aggregation
- Neurotrophic factors: BDNF, GDNF delivery
- Cell replacement: Stem cell transplantation
- Dopamine blockers: Tetrabenazine, deutetrabenazine
- ** Glutamate modulators**: Amantadine
- Deep brain stimulation: Target STN, GPe
- Gene therapy: AAV-based approaches